Epidemiologist Erin Bowles, MPH, is looking at cancer screening and treatment from many different perspectives. Her research brings new insight into cancer risk factors, diagnosis, treatment, and survivorship, while helping improve cancer care for patients and families.
Erin received an R50 mid-career research award from the National Cancer Institute (NCI). This award is given to cancer researchers who have demonstrated successes and contributions to cancer research as a non-principal investigator. As a key member of 2 large cancer collaborations — the NCI's Breast Cancer Surveillance Consortium and the Health Care Systems Cancer Research Network (CRN) — Erin has developed diverse expertise that includes reading mammograms for breast density and using administrative data to understand patterns of care in cancer treatment.
Her current work includes:
Erin’s experience working with large observational cohorts and collaborations with numerous study teams over the past 20 years has provided her with expertise in data collection and quality control for many subject areas. She is also a manager of the Collaborative Science Division at KPWHRI, providing leadership, supervision, mentorship, and support to junior faculty.
Breast cancer; colorectal cancer; multiple myeloma; thyroid cancer; pancreatic cancer; biostatistics; epidemiology; mammography; mammographic breast density; cancer treatment; cancer screening and surveillance; automated data collection; quality of care; medication use; care coordination; administrative data
Access to care; health disparities; health outcomes research; quality of life; measurement of change in health care systems; practice variation
Menopause; hormone replacement therapy (HRT); breast cancer
Cognitive health and dementia; biostatistics; epidemiology; medication use; cancer
Pharmacoepidemiology; observational study research methods; chemotherapy; radiation exposure
Aiello EJ, Buist DS, White E, Seger D, Taplin SH. Rate of breast cancer diagnoses among postmenopausal women with self-reported breast symptoms. J Am Board Fam Pract. 2004;17(6):408-15. PubMed
Frankenfeld CL, McTiernan A, Aiello EJ, Thomas WK, LaCroix K, Schramm J, Schwartz SM, Holt VL, Lampe JW. Mammographic density in relation to daidzein-metabolizing phenotypes in overweight, postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2004;13(7):1156-62. PubMed
Sparks R, Ulrich CM, Bigler J, Tworoger SS, Yasui Y, Rajan KB, Porter P, Stanczyk FZ, Ballard-Barbash R, Yuan X, Lin MG, McVarish L, Aiello EJ, McTiernan A. UDP-glucuronosyltransferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patients. Breast Cancer Res. 2004;6(5):R488-98. Epub 2004 Jun 29. PubMed
Tworoger SS, Chubak J, Aiello EJ, Yasui Y, Ulrich CM, Farin FM, Stapleton PL, Irwin ML, Potter JD, Schwartz RS, McTiernan A. The effect of CYP19 and COMT polymorphisms on exercise-induced fat loss in postmenopausal women. Obesity Research. 2004;12(6):972-81. PubMed
Tworoger SS, Chubak J, Aiello EJ, Ulrich CM, Atkinson C, Potter JD, Yasui Y, Stapleton PL, Lampe JW, Farin FM, Stanczyk FZ, McTiernan A. Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2004;13(1):94-101. PubMed
Aiello EJ, Yasui Y, Tworoger SS, Ulrich CM, Irwin ML, Bowen D, Schwartz RS, Kumai C, Potter JD, McTiernan A. Effect of a yearlong, moderate-intensity exercise intervention on the occurrence and severity of menopause symptoms in postmenopausal women. Menopause. 2004;11(4):382-388. PubMed
The division contributes to research across the institute with methodological and subject matter expertise.
Kaiser Permanente Washington has been part of the national Breast Cancer Surveillance Consortium since 1994. Learn about the Kaiser Permanente Washington Breast Cancer Surveillance Registry here.
How KPWHRI is contributing to better cancer screening and better outcomes for patients.
Cell by cell, scientists are building a high-resolution map of brain changes in Alzheimer’s disease.
Study suggests disparities at screening sites may influence lag in follow-ups.